The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 301–400 of 1,010
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Uscanga‐Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Támez-Guerra, R., Rodrı́guez-Padilla, C., & Alcocer-González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115688 · Cited by 116
Shahid, Z., Jain, T., Dioverti, M. V., Pennisi, M., Mikkilineni, L., Kambhampati, S., Shah, N. N., Dadwal, S., Papanicolaou, G. A., Hamadani, M., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.07.018 · Cited by 118
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 107
Vitale, C., & Strati, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00849 · Cited by 103
CAR-T cell potency: from structural elements to vector backbone components
Mazinani, M., & Rahbarizadeh, F. (2022) · Biomarker Research · doi:10.1186/s40364-022-00417-w · Cited by 111
Advances in immunotherapy for glioblastoma multiforme
Mahmoud, A. B., Ajina, R., Aref, S., Darwish, M., Alsayb, M. A., Taher, M., Alsharif, S. T., Hashem, A. M., & Alkayyal, A. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.944452 · Cited by 103
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma
Tomás, A. A., Fein, J. A., Fried, S., Flynn, J. R., Devlin, S. M., Fingrut, W. B., Anagnostou, T., Alperovich, A., Shah, N. N., Fraint, E., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01739-2 · Cited by 106
Self-citationDreyling, M. H., Fowler, N. H., Dickinson, M. J., Martínez‐López, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L. L., Chávez, J. C., Bachy, E., et al. (2024) · Blood · doi:10.1182/blood.2023021567 · Cited by 102
Self-citationBudde, L. E., Olszewski, A. J., Assouline, S. E., Lossos, I. S., Diefenbach, C., Kamdar, M. K., Ghosh, N., Modi, D., Sabry, W., Naik, S. G., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02726-5 · Cited by 105
Boroughs, A. C., Larson, R. C., Marjanovic, N. D., Gosik, K., Castaño, A. P., Porter, C. B. M., Lorrey, S., Ashenberg, O., Jerby‐Arnon, L., Hofree, M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.07.023 · Cited by 104
CAR-T cell therapy and infection: a review
Bupha‐Intr, O., Haeusler, G. M., Chee, L. C. Y., Thursky, K., Slavin, M. A., & Teh, B. W. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1855143 · Cited by 102
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac106 · Cited by 103
Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem
Sharma, N., Reagan, P. M., & Liesveld, J. L. (2022) · Cancers · doi:10.3390/cancers14061501 · Cited by 101
Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells
Kath, J., Du, W., Pruene, A., Braun, T., Thommandru, B., Turk, R., Sturgeon, M. L., Kurgan, G., Amini, L., Stein, M., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.018 · Cited by 103
Dose–response correlation for CAR-T cells: a systematic review of clinical studies
Rotte, A., Frigault, M. J., Ansari, A., Gliner, B., Heery, C. R., & Shah, B. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005678 · Cited by 108
Novel strategies for cancer immunotherapy: counter-immunoediting therapy
Liu, S., Sun, Q., & Ren, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01430-8 · Cited by 107
Bartlett, N. L., Assouline, S. E., Giri, P., Schuster, S. J., Cheah, C. Y., Matasar, M. J., Gregory, G. P., Yoon, D. H., Shadman, M. S., Fay, K. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009260 · Cited by 101
Self-citationPassweg, J. R., Baldomero, H., Atlija, M., Kleovoulou, I., Witaszek, A., Alexander, T., Angelucci, E., Averbuch, D., Bazarbachi, A. A., Ciceri, F., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02524-2 · Cited by 100
Recent updates on CAR T clinical trials for multiple myeloma
Lin, Q., Zhao, J., Song, Y., & Liu, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1092-1 · Cited by 101
The Landscape of CAR-T Cell Clinical Trials against Solid Tumors—A Comprehensive Overview
Schaft, N. (2020) · Cancers · doi:10.3390/cancers12092567 · Cited by 100
Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.521 · Cited by 104
Self-citationKeane, C., Law, S. C., Gould, C., Birch, S. E., Sabdia, M. B., de Long, L. M., Thillaiyampalam, G., Abro, E. U., Tobin, J. W. D., Tan, X., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001390 · Cited by 101
Wright, C. M., Lariviere, M. J., Baron, J. A., Uche, C. Z., Xiao, Y., Arscott, W. T., Anstadt, E. J., Barsky, A. R., Miller, D., LaRose, M. I., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.014 · Cited by 98
Self-citationHiltbrunner, S., Britschgi, C., Schuberth, P., Bankel, L., Nguyen‐Kim, T. D. L., Gulati, P., Weder, W., Opitz, I., Lauk, O., Caviezel, C., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.474 · Cited by 98
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A. C., Sotillo, E., Daugaard, M., Oo, H. Z., Liu, J., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0208 · Cited by 97
T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780442 · Cited by 99
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
Jia, Z., Ragoonanan, D. S., Mahadeo, K. M., Gill, J. B., Gorlick, R. G., Shpal, E., & Li, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952231 · Cited by 98
EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg9721 · Cited by 97
Imaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 99
Huarte, E., O’Connor, R. S., Peel, M. T., Nuñez-Cruz, S., Leferovich, J. M., Juvekar, A., Yang, Y., Truong, L., Huang, T., Naim, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1739 · Cited by 102
Myers, G. D., Verneris, M. R., Goy, A. H., & Maziarz, R. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002056 · Cited by 101
Self-citationInfectious complications of CAR T-cell therapy: a clinical update
Stewart, A. G., & Henden, A. S. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211036773 · Cited by 98
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 102
Self-citationUnderstanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes
Korell, F., Berger, T. R., & Maus, M. V. (2022) · Med · doi:10.1016/j.medj.2022.05.001 · Cited by 103
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
Kaiser, L., Hunter, Z. R., Treon, S. P., & Buske, C. (2020) · Leukemia · doi:10.1038/s41375-020-01102-3 · Cited by 96
Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E. M., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004155 · Cited by 96
The EBMT/EHA CAR-T Cell Handbook
Kröger, N., Gribben, J. G., Chabannon, C., Yakoub‐Agha, I., & Einsele, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-94353-0 · Cited by 106
PET/CT in Non-Hodgkin Lymphoma: An Update
Zanoni, L., Bezzi, D., Nanni, C., Paccagnella, A., Farina, A., Broccoli, A., Casadei, B., Zinzani, P. L., & Fanti, S. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.11.001 · Cited by 96
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
Athni, T. S., & Barmettler, S. (2023) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2023.01.018 · Cited by 108
Haghikia, A., Schett, G. A., & Mougiakakos, D. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00140-6 · Cited by 96
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Valeri, A., García-Ortiz, A., Castellano, E., Córdoba, L., Maroto-Martín, E., Encinas, J., Leivas, A., Río, P., & Martínez‐López, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.953849 · Cited by 96
Signaling pathways in brain tumors and therapeutic interventions
Li, S., Wang, C., Chen, J., Lan, Y., Zhang, W., Kang, Z., Zheng, Y., Zhang, R., Yu, J., & Li, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01260-z · Cited by 105
Tocchetti, C. G., Farmakis, D. T., Koop, Y., Andrés, M. S., Couch, L. S., Formisano, L., Ciardiello, F., Pane, F., Au, L., Emmerich, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3340 · Cited by 102
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Tao, Z., Chyra, Z., Kotulová, J., Celichowski, P., Mihályová, J., Charvátová, S., & Hájek, R. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01193-6 · Cited by 101
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96
Jain, M. D., Ziccheddu, B., Coughlin, C. A., Faramand, R., Griswold, A. J., Reid, K. M., Menges, M., Zhang, Y., Cen, L., Wang, X., et al. (2022) · Blood · doi:10.1182/blood.2021015008 · Cited by 91
Chou, C. K., & Turtle, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729735 · Cited by 92
Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells
Ashmore‐Harris, C., Iafrate, M., Saleem, A., & Fruhwirth, G. O. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.03.016 · Cited by 93
Clinical development of CAR T cell therapy in China: 2020 update
Wei, J., Guo, Y., Wang, Y., Wu, Z., Bo, J., Zhang, B., Zhu, J., & Han, W. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00555-x · Cited by 90
Baguet, C., Larghero, J., & Mebarki, M. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011992 · Cited by 95
Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma
Lin, L., Cho, S., Xing, L., Wen, K., Li, Y., Yu, T., Hsieh, P. A., Chen, H., Kurtoğlu, M., Zhang, Y., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0951-5 · Cited by 92
Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
Li, C., Mei, H., & Hu, Y. (2019) · Briefings in Functional Genomics · doi:10.1093/bfgp/elz042 · Cited by 97
Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
Roselli, E., Faramand, R. G., & Davila, M. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142030 · Cited by 90
Lee, Y.-H., Lee, H. J., Kim, H. C., Lee, Y., Nam, S. K., Hupperetz, C., Ma, J. S. Y., Wang, X., Singer, O., Kim, W. S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.004 · Cited by 89
Li, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 94
Teh, B. W., Yeoh, D. K., Haeusler, G. M., Yannakou, C. K., Fleming, S. A., Lindsay, J., & Slavin, M. A. (2021) · Internal Medicine Journal · doi:10.1111/imj.15588 · Cited by 89
Panowski, S. H., Srinivasan, S., Tan, N., Tacheva-Grigorova, S. K., Smith, B., Mak, Y. S. L., Ning, H., Villanueva, J., Wijewarnasuriya, D., Lang, S., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2931 · Cited by 94
Xie, B., Li, Z., Zhou, J., & Wang, W. (2022) · Cancers · doi:10.3390/cancers14133230 · Cited by 97
Applying a clinical lens to animal models of CAR-T cell therapies
Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.08.008 · Cited by 99
Passweg, J. R., Baldomero, H., Ciceri, F., Corbacioglu, S., de la Cámara, R., Dolstra, H., Glaß, B., Greco, R., McLornan, D. P., Neven, B., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-023-01943-3 · Cited by 89
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27312-6 · Cited by 88
Sauter, C. S., Sénéchal, B., Rivière, I., Ni, A., Bernal, Y. J., Wang, X., Purdon, T. J., Hall, M., Singh, A. N., Szenes, V., et al. (2019) · Blood · doi:10.1182/blood.2018883421 · Cited by 88
Ahmad, A., Shahab Uddin, M. S., & Steinhoff, M. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113906 · Cited by 91
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Reagan, P. M., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003848 · Cited by 88
Passweg, J. R., Baldomero, H., Ciceri, F., de la Cámara, R., Glaß, B., Greco, R., Hazenberg, M. D., Kałwak, K., McLornan, D. P., Neven, B., et al. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02248-9 · Cited by 88
Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Shankar, K., Capitini, C. M., & Saha, K. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01741-4 · Cited by 85
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Rodriguez-Marquez, P., Calleja-Cervantes, M. E., Serrano, G., Oliver-Caldes, A., Palacios-Berraquero, M. L., Martin-Mallo, A., Calviño, C., Español-Rego, M., Ceballos, C., Lozano, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo0514 · Cited by 109
Updates on CAR T‐cell therapy in B‐cell malignancies
Jacoby, E., Shahani, S. A., & Shah, N. N. (2019) · Immunological Reviews · doi:10.1111/imr.12774 · Cited by 90
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
Titov, A., Valiullina, A., Zmievskaya, E., Zaikova, E. K., Petukhov, A., Рифкатовна, М. Р., Bulatov, E., & Rizvanov, A. A. (2020) · Cancers · doi:10.3390/cancers12010125 · Cited by 89
Diffuse large B-cell lymphoma: new targets and novel therapies
Cheson, B. D., Nowakowski, G. S., & Salles, G. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00456-w · Cited by 87
Self-citationPolymer- and lipid-based gene delivery technology for CAR T cell therapy
Pinto, I. S., Cordeiro, R. A., & Faneca, H. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.038 · Cited by 89
YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies
Chen, Z., Zeng, C., Yang, L., Che, Y., Chen, M., Sau, L., Wang, B., Zhou, K., Chen, Y., Qing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.11.007 · Cited by 90
Timmers, M., Roex, G., Wang, Y., Campillo-Davó, D., Tendeloo, V. F. V., Chu, Y., Berneman, Z. N., Luo, F., Acker, H. H. V., & Anguille, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01613 · Cited by 86
Bishop, M. R., Maziarz, R. T., Waller, E. K., Jaeger, U., Westin, J. R., McGuirk, J. P., Fleury, I., Holte, H., Borchmann, P., del Corral, C., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000151 · Cited by 87
Self-citationNoncoding RNAs as potential mediators of resistance to cancer immunotherapy
Vishnubalaji, R., Shaath, H., Elango, R., & Alajez, N. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.006 · Cited by 82
Okusaka, T., & Furuse, J. (2020) · Journal of Gastroenterology · doi:10.1007/s00535-020-01666-y · Cited by 88
Heme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages
Alaluf, E., Vokaer, B., Detavernier, A., Azouz, A., Splittgerber, M., Carrette, A., Boon, L., Libert, F., Soares, M. P., Moine, A. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133929 · Cited by 86
Improving outcomes and mitigating costs associated with CAR T-cell therapy
Rebecca Borgert, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88737 · Cited by 87
Aspuria, P.-J. P., Vivona, S., Bauer, M., Semana, M., Ratti, N. P., McCauley, S., Riener, R. M., Malefyt, R. D. W., Rokkam, D., Emmerich, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg7565 · Cited by 86
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
Qayed, M. D., McGuirk, J. P., Myers, G. D., Parameswaran, V., Waller, E. K., Holman, P., Rodrigues, M., Clough, L. F., & Willert, J. R. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.05.003 · Cited by 88
Self-citationLemoine, J., Bachy, E., Cartron, G., Beauvais, D., Gastinne, T., Blasi, R. D., Rubio, M., Guidez, S., Mohty, M., Casasnovas, O., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010624 · Cited by 85
Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
Watanabe, N., McKenna, M. K., Shaw, A. R., & Suzuki, M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.023 · Cited by 84
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies
Walti, C. S., Krantz, E. M., Maalouf, J., Boonyaratanakornkit, J. B., Keane-Candib, J., Joncas-Schronce, L., Stevens‐Ayers, T., Dasgupta, S., Taylor, J. J., Hirayama, A. V. V., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.146743 · Cited by 86
Oncologic emergencies and urgencies: A comprehensive review
Rothberg, B. E. G., Quest, T. E., Yeung, S. J., Pelosof, L. C., Gerber, D. E., Seltzer, J. A., Bischof, J. J., Thomas, C. R., Akhter, N., Mamtani, M., et al. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21727 · Cited by 95
Xue, D., Lu, S., Zhang, H., Li, Z., Dai, Z., Kaufman, D. S., & Zhang, J. (2023) · Trends in biotechnology · doi:10.1016/j.tibtech.2023.02.003 · Cited by 86
Maziarz, R. T., Waller, E. K., Jaeger, U., Fleury, I., McGuirk, J. P., Holte, H., Jaglowski, S. M., Schuster, S. J., Bishop, M. R., Westin, J. R., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001026 · Cited by 83
Self-citationCoyle, L. A., Morley, N. J., Rambaldi, A., Mason, K. D., Verhoef, G. E. G., Furness, C. L., Zhang, A., Jung, A. S., Cohan, D. M., & Franklin, J. L. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1759055 · Cited by 83
Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity
Foster, M. C., Savoldo, B., Lau, W., Rubiños, C., Grover, N. S., Armistead, P. M., Coghill, J. M., Hagan, R. S., Morrison, K., Buchanan, F. B., et al. (2021) · Blood · doi:10.1182/blood.2021010784 · Cited by 85
Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy
Tedesco, V. E., & Mohan, C. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001249 · Cited by 84
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
Zurko, J. C., Ramdial, J., Shadman, M. S., Ahmed, S., Szabó, A., Iovino, L., Tomás, A. A., Sauter, C. S., Perales, M., Shah, N. N., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281242 · Cited by 83
Self-citationCardiovascular Considerations Before Cancer Therapy
Raisi‐Estabragh, Z., Murphy, A. C., Ramalingam, S., Scherrer‐Crosbie, M., López‐Fernández, T., Reynolds, K. L., Aznar, M. C., Lin, A. E., Libby, P., Córdoba, R., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.07.017 · Cited by 93
Fan, F., Yoo, H. J., Stock, S., Wang, L., Liu, Y., Schubert, M., Wang, S., Neuber, B., Hückelhoven‐Krauss, A., Gern, U., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33212 · Cited by 82
Faramand, R. G., Jain, M. D., Staedtke, V., Kotani, H., Bai, R.-Y., Reid, K. M., Lee, S. B., Spitler, K., Wang, X., Cao, B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1434 · Cited by 88
Engineering Gene Therapy: Advances and Barriers
Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 87
Saini, N. Y., Swoboda, D. M., Greenbaum, U., Ma, J., Patel, R. D., Devashish, K., Das, K., Tanner, M. R., Strati, P., Nair, R. K., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0177 · Cited by 86
Self-citationZhang, H., Bu, C., Peng, Z., Li, G., Zhou, Z., Ding, W. Y., Zheng, Y., He, Y., Hu, Z., Pei, K., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01703-0 · Cited by 85
Recent Advances in CAR-Based Solid Tumor Immunotherapy
Shin, M. H., Oh, E., Kim, Y. J., Nam, D.-H., Jeon, S., Yu, J. H., & Minn, D. (2023) · Cells · doi:10.3390/cells12121606 · Cited by 86
Minson, A. G., Hamad, N., Cheah, C. Y., Tam, C. S. L., Blombery, P. A., Westerman, D., Ritchie, D., Morgan, H., Holzwart, N., Lade, S., et al. (2023) · Blood · doi:10.1182/blood.2023021306 · Cited by 87
Self-citationElsallab, M., Levine, B. L., Wayne, A. S., & Abou-El-Enein, M. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30729-6 · Cited by 81
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients
Di, M., Huntington, S. F., & Olszewski, A. J. (2020) · The Oncologist · doi:10.1002/onco.13610 · Cited by 81
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
